IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Mind Medicine, Inc.	Confirmation No.:
Serial No.:	17/833,829	Group No.:
Filing or 371(c) Date:	6 June 2022	Examiner:

Entitled: CONTROLLING EFFECTS AFTER 5HT2A AGONISTS ADMINISTRATION

THIRD-PARTY PRE-ISSUANCE SUBMISSION

Examiner:

The following documents, which are also identified in the Form PTO/SB/429 filed herewith, are submitted for your consideration as being of potential relevance to the examination of the present application:

1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)
2. VALERIANI (2015) "Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms" Human Psychopharmacology: Clinical and Experimental. 30:249-254.
3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844
4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109
5. MAHATMAGANJA (2007) "Mood Stabilizers Cancel Trip Mushrooms, Olanzapine (Zyprexa) & Fluoxetine (Prozac)" Retrieved from 05 September 2007. URL: https://web.archive.org/web/20070905190454/https://erowid.org/experiences/exp.php?ID=44850
6. BIGWOOD (1982) "Variation of psilocybin and psilocin levels with repeated flushes (harvests) of mature sporocarps of *Psilocybe cubensis* (earle) singer" Journal of Ethnopharmacology. 5(3):287-291.

7. LEVICH (2020) “Psychedelic Dosage Guide: How Much of Each Substance to Take” Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psychedelicpassage.com/psychedelic-dosage-guide-how-much-of-each-substance-to-take/
8. FDA (2016) “NUPLAZID (PIMAVANSERIN): HIGHLIGHTS OF PRESCRIBING INFORMATION” URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf
9. NIMH (2021) “Understanding Psychosis” Retrieved 13 May 2021. URL: https://web.archive.org/web/20210503133654/https://www.nimh.nih.gov/health/publications/understanding-psychosis/

Attached hereto is a claim chart providing a concise description of the relevance of each reference in the document list to the elements of the presently pending claims.

U.S.S.N. 17/833,829 Pending Claims	**References**
1. A composition for treating an individual while reducing acute effects, comprising effective amounts of a psychedelic drug and a duration shortening agent.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy; wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **claim 3** "The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula (I)** is **selected from the group consisting of N,N-**

	dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N-diethyltryptamine, N,N-dipropyltryptamine and N,N-diisopropyltryptamine." From **claim 4** "The **combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is** selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, **Pimavanserin**, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK-215083, Cyamemazine, Mesulergine, BF-1 , LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**"
2. The composition of claim 1, wherein said psychedelic drug is a 5HT2A agonist chosen from the group consisting of LSD, psilocybin, psilocin, mescaline, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), dimethyltryptamine (DMT), 2,5-dimethoxy-4-iodoamphetamine (DOI), 2,5-dimethoxy-4-bromoamphetamie (DOB), salts thereof, tartrates thereof, solvates thereof, isomers thereof, deuterated forms thereof, analogs thereof, and homologues thereof.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;

	wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy; wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **claim 3** "The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula (I)** is selected from the group consisting of **N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine**, N,N-diethyltryptamine, N,N-dipropyltryptamine and N,N-diisopropyltryptamine." From **claim 4** "The **combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is** selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, **Pimavanserin**, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK-215083, Cyamemazine, Mesulergine, BF-1 , LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**"
3. The composition of claim 1, wherein said psychedelic drug is present in an amount	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)

that provides an effect for at least 2 hours.	From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy; wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **claim 3** "The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula (I)** is selected from the group consisting of **N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N-diethyltryptamine, N,N-dipropyltryptamine and N,N-diisopropyltryptamine.**" From **claim 4** "The **combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is** selected from the group consisting of Methiothepin, Ritanserin,

	Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, **Pimavanserin**, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK-215083, Cyamemazine, Mesulergine, BF-1 , LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**" From **page 29** "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise **0.5 -1000 mg of a compound described by formula (I)** and/or 0.5 - 1000 mg of a 5-HT2A receptor antagonist." 2. VALERIANI (2015) "Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms" Human Psychopharmacology: Clinical and Experimental. 30:249-254. From **page 250** "In most cases, users reported here to **ingest olanzapine at relatively small dosages, usually ranging from 5 to 10 mg** once a day for just a few days **as a "terminator"/"modulator" of unwanted NPS psychedelic effects**." From **page 251** "Most online reports about olanzapine were here related to its use as a short-term, self-prescribed treatment for the psychedelic crises/"bad trips." Symptoms of psychedelic crises usually last a few hours, depending on the drug taken and dose ingested (Mangot, 2013). Indeed, SC's effects may last 1–4 h (Hoyte et al., 2012); tryptamines' effects 2–6 h (Hallock et al., 2013); lysergic acid diethylamide [LSD] 6–14 h (Krebs and Johansen, 2013); and mescaline 8–16 h (Trachsel, 2012)." From **page 251** "There are already published data showing the effectiveness of olanzapine and, in general, of second-generation antipsychotics (SGA), as first-line treatments in psychotic disorders

induced by drugs such as cannabis (Bersani et al., 2002a, 2002b; Sevy et al., 2011) and cocaine (Testa et al., 2013). Compared with first-generation antipsychotics (FGA), SGA may present with some advantages while treating drug-induced psychosis, including the following: (i) SGA induce fewer/no extrapyramidal symptoms (Ohno et al., 2013); (ii) SGA quickly dissociate from D2 receptors, unlike FGA/haloperidol, and hence may seem to be less associated with dysphoria and interference with drug reward anticipation/craving (Juckel et al., 2006); (iii) SGA seem more effective in the treatment of negative symptoms (Buchanan et al., 2005), alter positively mood (McIntyre et al., 2004), and have a positive impact on cognition (Bersani et al., 2011); and (iv) **SGA act as antagonists of 5HT2A receptor, which is the main target of most hallucinogenic drugs** (Potvin et al., 2003). From this point of view, **both clozapine and olanzapine may present with a distinct advantage in reducing drug-induced psychotic symptoms** (Murthy and Chand, 2012)."

5. MAHATMAGANJA (2007) "Mood Stabilizers Cancel Trip Mushrooms, Olanzapine (Zyprexa) & Fluoxetine (Prozac)" Retrieved from 05 September 2007. https://web.archive.org/web/20070905190454/https://erowid.org/experiences/exp.php?ID=44850

"For the past 2 months I have been taking 6 mg Zyprexa and 25 mg Prozac under the name Symbyax daily. I have taken mushrooms before, but never while on Symbyax. **Tonight I ate one gram of powerful mushrooms with no effects after 4 hours.** I did some research and found a report of a person **eating 8 g of cubensis mushrooms while on Zyprexa with no effects**"

6. BIGWOOD (1982) "Variation of psilocybin and psilocin levels with repeated flushes (harvests) of mature sporocarps of Psilocybe cubensis (earle) singer" Journal of Ethnopharmacology. 5(3):287-291.

From **page 289**

TABLE 1

The dry weight variation of psilocybin and psilocin levels in *Psilocybe cubensis* as a function of flush number (quantified by HPLC)

Flush No.	Miniculture No. 1		Miniculture No. 2		Miniculture No. 3	
	Psilocybin (mg/g)	Psilocin (mg/g)	Psilocybin (mg/g)	Psilocin (mg/g)	Psilocybin (mg/g)	Psilocin (mg/g)
1	8.3	0.5	5.1	0	7.6	0
2	6.5	1.5	7.3	0	6.2	0
3	13.3	1.0	4.7	1.7	5.3	0.9
4	4.8	2.6	3.7	2.9	3.2	1.8
5	—	—	5.2	2.2	6.7	1.7
6	6.8	0.5	—	—	—	—

3. PHARMBOY (2013) “Cheating Hofmann - LSD, Quetiapine & Alcohol” Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 25** “Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit.”

7. LEVICH (2020) “Psychedelic Dosage Guide: How Much of Each Substance to Take” Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psychedelicpassage.com/psychedelic-dosage-guide-how-much-of-each-substance-to-take/

“Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 – 150 µg (micrograms) per individual, 200+ µg in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 µg per tab**.”

4. GUZMAN (2016) “Mechanism of Action of Quetiapine” URL: https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109

	From **paragraph 5** "**Quetiapine has antagonist actions at 5-HT2A receptors**, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
4. The composition of claim 3, wherein said psychedelic drug is present in an amount chosen from the group consisting of 0.01-1 mg LSD, 10-50 mg psilocybin, 100-800 mg mescaline, 20-100 mg DMT, 0.1-5 mg DOI, and 0.1-5 mg DOB.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein **R1 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R2 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R3 is** selected from the group consisting of **hydrogen**, methoxy, methyl, hydroxy and a halogen; and wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy; wherein **R5 is** selected from the group consisting of deuterium (2H) and **protium (1H)**; **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament."

	From **claim 3** "The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula (I)** is selected from the group consisting of **N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine**, N,N-diethyltryptamine, N,N-dipropyltryptamine and N,N-diisopropyltryptamine." From **page 29** "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise **0.5 -1000 mg of a compound described by formula (I)** and/or 0.5 - 1000 mg of a 5-HT2A receptor antagonist." 2. VALERIANI (2015) "Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms" Human Psychopharmacology: Clinical and Experimental. 30:249-254. From **page 250** "In most cases, users reported here to **ingest olanzapine at relatively small dosages, usually ranging from 5 to 10 mg** once a day for just a few days **as a "terminator"/"modulator" of unwanted NPS psychedelic effects**." From **page 251** "Most online reports about olanzapine were here related to its use as a short-term, self-prescribed treatment for the psychedelic crises/"bad trips." Symptoms of psychedelic crises usually last a few hours, depending on the drug taken and dose ingested (Mangot, 2013). Indeed, SC's effects may last 1–4 h (Hoyte et al., 2012); tryptamines' effects 2–6 h (Hallock et al., 2013); lysergic acid diethylamide [LSD] 6–14 h (Krebs and Johansen, 2013); and mescaline 8–16 h (Trachsel, 2012)." From **page 251** "There are already published data showing the effectiveness of olanzapine and, in general, of second-generation antipsychotics (SGA), as first-line treatments in psychotic disorders induced by drugs such as cannabis (Bersani et al., 2002a, 2002b; Sevy et al., 2011) and cocaine (Testa et al., 2013). Compared with first-generation antipsychotics (FGA), SGA may present with some advantages while treating drug-induced psychosis, including the following: (i) SGA induce fewer/no extrapyramidal symptoms (Ohno et al., 2013); (ii) SGA quickly dissociate from D2 receptors, unlike FGA/haloperidol, and hence may seem to be less associated with dysphoria and interference with drug reward

	anticipation/craving (Juckel et al., 2006); (iii) SGA seem more effective in the treatment of negative symptoms (Buchanan et al., 2005), alter positively mood (McIntyre et al., 2004), and have a positive impact on cognition (Bersani et al., 2011); and (iv) **SGA act as antagonists of 5HT2A receptor, which is the main target of most hallucinogenic drugs** (Potvin et al., 2003). From this point of view, **both clozapine and olanzapine may present with a distinct advantage in reducing drug-induced psychotic symptoms** (Murthy and Chand, 2012)." 5. MAHATMAGANJA (2007) "Mood Stabilizers Cancel Trip Mushrooms, Olanzapine (Zyprexa) & Fluoxetine (Prozac)" Retrieved from 05 September 2007. https://web.archive.org/web/20070905190454/https://erowid.org/experiences/exp.php?ID=44850  "For the past 2 months I have been taking 6 mg Zyprexa and 25 mg Prozac under the name Symbyax daily. I have taken mushrooms before, but never while on Symbyax. **Tonight I ate one gram of powerful mushrooms with no effects after 4 hours.** I did some research and found a report of a person **eating 8 g of cubensis mushrooms while on Zyprexa with no effects**" 6. BIGWOOD (1982) "Variation of psilocybin and psilocin levels with repeated flushes (harvests) of mature sporocarps of Psilocybe cubensis (earle) singer" Journal of Ethnopharmacology. 5(3):287-291. From page 289

TABLE 1

The dry weight variation of psilocybin and psilocin levels in *Psilocybe cubensis* as a function of flush number (quantified by HPLC)

Flush No.	Miniculture No. 1		Miniculture No. 2		Miniculture No. 3	
	Psilocybin (mg/g)	Psilocin (mg/g)	Psilocybin (mg/g)	Psilocin (mg/g)	Psilocybin (mg/g)	Psilocin (mg/g)
1	8.3	0.5	5.1	0	7.6	0
2	6.5	1.5	7.3	0	6.2	0
3	13.3	1.0	4.7	1.7	5.3	0.9
4	4.8	2.6	3.7	2.9	3.2	1.8
5	—	—	5.2	2.2	6.7	1.7
6	6.8	0.5	—	—	—	—

3. PHARMBOY (2013) “Cheating Hofmann - LSD, Quetiapine & Alcohol” Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 25** “Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit.”

7. LEVICH (2020) “Psychedelic Dosage Guide: How Much of Each Substance to Take” Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psychedelicpassage.com/psychedelic-dosage-guide-how-much-of-each-substance-to-take/

“Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 – 150 µg (micrograms) per individual, 200+ µg in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 µg per tab**.”

4. GUZMAN (2016) “Mechanism of Action of Quetiapine” URL: https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109

	From **paragraph 5** "**Quetiapine has antagonist actions at 5-HT2A receptors**, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
5. The composition of claim 1, wherein said duration shortening agent is a 5HT2A receptor antagonist.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein **R1 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R2 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R3 is** selected from the group consisting of **hydrogen**, methoxy, methyl, hydroxy and a halogen; and wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy; wherein **R5 is** selected from the group consisting of **deuterium (2H) and protium (1H)**; **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament."

6. The composition of claim 5, wherein said duration shortening agent is chosen from the group consisting of pimavanserin, salts thereof, analogs thereof, and homologs thereof.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein **R1 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R2 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R3 is** selected from the group consisting of **hydrogen**, methoxy, methyl, hydroxy and a halogen; and wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy; wherein **R5 is** selected from the group consisting of **deuterium (2H) and protium (1H)**; **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **claim 4** "The **combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is** selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone,

	Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, **Pimavanserin**, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK-215083, Cyamemazine, Mesulergine, BF-1 , LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**"
7. The composition of claim 6, wherein said pimavanserin is present in an amount of 1-100 mg.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein **R1 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R2 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R3 is** selected from the group consisting of **hydrogen**, methoxy, methyl, hydroxy and a halogen; and

	wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy; wherein **R5 is** selected from the group consisting of **deuterium (2H) and protium (1H)**; **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **claim 4** "The **combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is** selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, **Pimavanserin**, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK-215083, Cyamemazine, Mesulergine, BF-1 , LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**" From **page 29** "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise **0.5 -1000 mg of a compound described by formula (I)** and/or **0.5 - 1000 mg of a 5-HT2A receptor antagonist**." 8. FDA (2016) "NUPLAZID (PIMAVANSERIN): HIGHLIGHTS OF PRESCRIBING INFORMATION" URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf From **page 1** "DOSAGE AND ADMINISTRATION: **Recommended dose is 34 mg**, taken orally as two 17 mg tablets once daily, without titration."
8. The composition of claim 1, wherein said	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL

psychedelic drug and duration shortening agent are in dosage units chosen from the group consisting of separate dosage units, in the same dosage unit with the same release profiles, and in the same dosage unit with different release profiles.	AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein **R1 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R2 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R3 is** selected from the group consisting of **hydrogen**, methoxy, methyl, hydroxy and a halogen; and wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy; wherein **R5 is** selected from the group consisting of **deuterium (2H) and protium (1H)**; **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **page 15** "The term "combination product' can refer to **(i) a product comprised of two or more regulated components that are physically, chemically, or otherwise combined or mixed and produced as a single entity;** (ii) t**wo or more separate products packaged together** in a single package or as a unit and comprised of drug and device products, device and biological products, or biological and drug products; (iii) a drug, device, or biological

	product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device, or biological product where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose; or (iv) any investigational drug, device, or biological product packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device, or biological product where both are required to achieve the intended use, indication, or effect."
9. A method of treating an individual with a psychedelic drug and reducing or eliminating its acute duration of action, including the steps of: administering a psychedelic drug to the individual; administering a duration shortening and/or effect blocking agent to the individual; and shortening and/or reducing and/or eliminating the acute effects of the psychedelic drug.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein **R1 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R2 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R3 is** selected from the group consisting of **hydrogen**, methoxy, methyl, hydroxy and a halogen; and wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy;

	wherein **R5 is** selected from the group consisting of **deuterium (2H) and protium (1H)**; **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**"
10. The method of claim 9, wherein the duration shortening agent is administered 1 minute to 24 hours after administering the psychedelic drug.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein **R1 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R2 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R3 is** selected from the group consisting of **hydrogen**, methoxy, methyl, hydroxy and a halogen; and wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy;

	wherein **R5 is** selected from the group consisting of **deuterium (2H) and protium (1H)**; **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**" From **page 32** "A compound described by **formula (I) and a 5-HT2A receptor antagonist may be administered together or separately** to an individual who suffers from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders. From **page 32** "In a preferred embodiment, a compound described by formula (I) may be administered to an individual who is already being administered a 5-HT2A receptor antagonist and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders. Conversely, in an alternative embodiment, **a 5-HT2A receptor antagonist may be administered to an individual who is already being administered a compound described by formula (I)** and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders."
11. The method of claim 9, wherein the psychedelic drug is a 5HT2A agonist chosen from the group consisting of LSD, psilocybin, psilocin, mescaline, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), dimethyltryptamine (DMT), 2,5-dimethoxy-4-iodoamphetamine	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:

(DOI), 2,5-dimethoxy-4-bromoamphetamie (DOB), salts thereof, tartrates thereof, solvates thereof, isomers thereof, deuterated forms thereof, analogs thereof, and homologues thereof.	 wherein **R1 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R2 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R3 is** selected from the group consisting of **hydrogen**, methoxy, methyl, hydroxy and a halogen; and wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy; wherein **R5 is** selected from the group consisting of deuterium (2H) and **protium (1H)**; **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **claim 3** "The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula (I)** is selected from the group consisting of **N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N-diethyltryptamine, N,N-dipropyltryptamine and N,N-diisopropyltryptamine.**" From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**"

12. The method of claim 9, wherein the psychedelic drug is administered in an amount that provides an effect for at least 2 hours.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein **R1 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R2 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R3 is** selected from the group consisting of **hydrogen**, methoxy, methyl, hydroxy and a halogen; and wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy; wherein **R5 is** selected from the group consisting of deuterium (2H) and **protium (1H)**; **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **claim 3** "The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula (I)** is selected from the group consisting of **N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N-**

	diethyltryptamine, N,N-dipropyltryptamine and N,N-diisopropyltryptamine." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**" 2. VALERIANI (2015) "Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms" Human Psychopharmacology: Clinical and Experimental. 30:249-254. From **page 250** "In most cases, users reported here to **ingest olanzapine at relatively small dosages, usually ranging from 5 to 10 mg** once a day for just a few days **as a "terminator"/"modulator" of unwanted NPS psychedelic effects**." From **page 251** "Most online reports about olanzapine were here related to its use as a short-term, self-prescribed treatment for the psychedelic crises/"bad trips." Symptoms of psychedelic crises usually last a few hours, depending on the drug taken and dose ingested (Mangot, 2013). Indeed, SC's effects may last 1–4 h (Hoyte et al., 2012); tryptamines' effects 2–6 h (Hallock et al., 2013); lysergic acid diethylamide [LSD] 6–14 h (Krebs and Johansen, 2013); and mescaline 8–16 h (Trachsel, 2012)." From **page 251** "There are already published data showing the effectiveness of olanzapine and, in general, of second-generation antipsychotics (SGA), as first-line treatments in psychotic disorders induced by drugs such as cannabis (Bersani et al., 2002a, 2002b; Sevy et al., 2011) and cocaine (Testa et al., 2013). Compared with first-generation antipsychotics (FGA), SGA may present with some advantages while treating drug-induced psychosis, including the following: (i) SGA induce fewer/no extrapyramidal symptoms (Ohno et al., 2013); (ii) SGA quickly dissociate from D2 receptors, unlike FGA/haloperidol, and hence may seem to be less associated with dysphoria and interference with drug reward anticipation/craving (Juckel et al., 2006); (iii) SGA seem more effective in the treatment of negative symptoms (Buchanan et al., 2005), alter positively mood (McIntyre et al., 2004), and have a positive impact on cognition (Bersani et al., 2011); and (iv) **SGA act as antagonists of 5HT2A receptor, which is the main target of most hallucinogenic drugs** (Potvin et al., 2003). From this point

of view, **both clozapine and olanzapine may present with a distinct advantage in reducing drug-induced psychotic symptoms** (Murthy and Chand, 2012)."

5. MAHATMAGANJA (2007) "Mood Stabilizers Cancel Trip Mushrooms, Olanzapine (Zyprexa) & Fluoxetine (Prozac)" Retrieved from 05 September 2007. https://web.archive.org/web/20070905190454/https://erowid.org/experiences/exp.php?ID=44850

"For the past 2 months I have been taking 6 mg Zyprexa and 25 mg Prozac under the name Symbyax daily. I have taken mushrooms before, but never while on Symbyax. **Tonight I ate one gram of powerful mushrooms with no effects after 4 hours.** I did some research and found a report of a person **eating 8 g of cubensis mushrooms while on Zyprexa with no effects**"

6. BIGWOOD (1982) "Variation of psilocybin and psilocin levels with repeated flushes (harvests) of mature sporocarps of Psilocybe cubensis (earle) singer" Journal of Ethnopharmacology. 5(3):287-291.

From **page 289**

TABLE 1

The dry weight variation of psilocybin and psilocin levels in *Psilocybe cubensis* as a function of flush number (quantified by HPLC)

Flush No.	Miniculture No. 1		Miniculture No. 2		Miniculture No. 3	
	Psilocybin (mg/g)	Psilocin (mg/g)	Psilocybin (mg/g)	Psilocin (mg/g)	Psilocybin (mg/g)	Psilocin (mg/g)
1	8.3	0.5	5.1	0	7.6	0
2	6.5	1.5	7.3	0	6.2	0
3	13.3	1.0	4.7	1.7	5.3	0.9
4	4.8	2.6	3.7	2.9	3.2	1.8
5	—	—	5.2	2.2	6.7	1.7
6	6.8	0.5	—	—	—	—

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

	 From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit." 7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psychedelicpassage.com/psychedelic-dosage-guide-how-much-of-each-substance-to-take/ "Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 – 150 µg (micrograms) per individual, 200+ µg in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 µg per tab**." 4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109 From **paragraph 5** "**Quetiapine has antagonist actions at 5-HT2A receptors**, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
13. The method of claim 12, wherein the psychedelic drug is administered in an amount chosen from the group consisting of 0.01-1 mg LSD, 10-50 mg psilocybin, 100-800 mg mescaline, 20-100 mg DMT, 0.1-5 mg	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:

DOI, and 0.1-5 mg DOB.	 wherein **R1 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R2 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R3 is** selected from the group consisting of **hydrogen**, methoxy, methyl, hydroxy and a halogen; and wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy; wherein **R5 is** selected from the group consisting of **deuterium (2H) and protium (1H)**; **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **page 29** "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise **0.5 -1000 mg of a compound described by formula (I)** and/or 0.5 - 1000 mg of a 5-HT2A receptor antagonist." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**"

	2. VALERIANI (2015) “Olanzapine as the ideal “trip terminator”? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms” Human Psychopharmacology: Clinical and Experimental. 30:249-254. From **page 250** “In most cases, users reported here to **ingest olanzapine at relatively small dosages, usually ranging from 5 to 10 mg** once a day for just a few days **as a “terminator”/“modulator” of unwanted NPS psychedelic effects**.” From **page 251** “Most online reports about olanzapine were here related to its use as a short-term, self-prescribed treatment for the psychedelic crises/“bad trips.” Symptoms of psychedelic crises usually last a few hours, depending on the drug taken and dose ingested (Mangot, 2013). Indeed, SC's effects may last 1–4 h (Hoyte et al., 2012); tryptamines' effects 2–6 h (Hallock et al., 2013); lysergic acid diethylamide [LSD] 6–14 h (Krebs and Johansen, 2013); and mescaline 8–16 h (Trachsel, 2012).” From **page 251** “There are already published data showing the effectiveness of olanzapine and, in general, of second-generation antipsychotics (SGA), as first-line treatments in psychotic disorders induced by drugs such as cannabis (Bersani et al., 2002a, 2002b; Sevy et al., 2011) and cocaine (Testa et al., 2013). Compared with first-generation antipsychotics (FGA), SGA may present with some advantages while treating drug-induced psychosis, including the following: (i) SGA induce fewer/no extrapyramidal symptoms (Ohno et al., 2013); (ii) SGA quickly dissociate from D2 receptors, unlike FGA/haloperidol, and hence may seem to be less associated with dysphoria and interference with drug reward anticipation/craving (Juckel et al., 2006); (iii) SGA seem more effective in the treatment of negative symptoms (Buchanan et al., 2005), alter positively mood (McIntyre et al., 2004), and have a positive impact on cognition (Bersani et al., 2011); and (iv) **SGA act as antagonists of 5HT2A receptor, which is the main target of most hallucinogenic drugs** (Potvin et al., 2003). From this point of view, **both clozapine and olanzapine may present with a distinct advantage in reducing drug-induced psychotic symptoms** (Murthy and Chand, 2012).” 5. MAHATMAGANJA (2007) “Mood Stabilizers Cancel Trip Mushrooms, Olanzapine (Zyprexa) & Fluoxetine (Prozac)” Retrieved from 05 September 2007.

https://web.archive.org/web/20070905190454/https://erowid.org/experiences/exp.php?ID=44850

"For the past 2 months I have been taking 6 mg Zyprexa and 25 mg Prozac under the name Symbyax daily. I have taken mushrooms before, but never while on Symbyax. **Tonight I ate one gram of powerful mushrooms with no effects after 4 hours.** I did some research and found a report of a person **eating 8 g of cubensis mushrooms while on Zyprexa with no effects**"

6. BIGWOOD (1982) "Variation of psilocybin and psilocin levels with repeated flushes (harvests) of mature sporocarps of Psilocybe cubensis (earle) singer" Journal of Ethnopharmacology. 5(3):287-291.

From **page 289**

TABLE 1

The dry weight variation of psilocybin and psilocin levels in *Psilocybe cubensis* as a function of flush number (quantified by HPLC)

Flush No.	Miniculture No. 1		Miniculture No. 2		Miniculture No. 3	
	Psilocybin (mg/g)	Psilocin (mg/g)	Psilocybin (mg/g)	Psilocin (mg/g)	Psilocybin (mg/g)	Psilocin (mg/g)
1	8.3	0.5	5.1	0	7.6	0
2	6.5	1.5	7.3	0	6.2	0
3	13.3	1.0	4.7	1.7	5.3	0.9
4	4.8	2.6	3.7	2.9	3.2	1.8
5	—	—	5.2	2.2	6.7	1.7
6	6.8	0.5	—	—	—	—

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

	From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit." 7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psychedelicpassage.com/psychedelic-dosage-guide-how-much-of-each-substance-to-take/ "Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 – 150 µg (micrograms) per individual, 200+ µg in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 µg per tab**." 4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109 From **paragraph 5** "**Quetiapine has antagonist actions at 5-HT2A receptors**, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
14. The method of claim 9, wherein the duration shortening agent is a 5HT2A receptor antagonist.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:



wherein **R1 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl;

wherein **R2 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl;

wherein **R3 is** selected from the group consisting of **hydrogen**, methoxy, methyl, hydroxy and a halogen; and

wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy;

wherein **R5 is** selected from the group consisting of **deuterium (2H) and protium (1H)**; **and**

(ii) a 5-HT2A receptor antagonist;

for use as a medicament."

From **claim 3** "The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula (I)** is selected from the group consisting of **N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N-diethyltryptamine, N,N-dipropyltryptamine and N,N-diisopropyltryptamine.**"

From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**"

15. The method of claim 14, wherein the duration shortening agent is chosen from the group consisting of pimavanserin, salts thereof, analogs thereof, and homologs thereof.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein **R1 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R2 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R3 is** selected from the group consisting of **hydrogen**, methoxy, methyl, hydroxy and a halogen; and wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy; wherein **R5 is** selected from the group consisting of **deuterium (2H) and protium (1H)**; **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **claim 3** "The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula (I)** is selected from the group consisting of **N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N-**

	diethyltryptamine, N,N-dipropyltryptamine and N,N-diisopropyltryptamine." From **claim 4** "The **combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is** selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, **Pimavanserin**, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK-215083, Cyamemazine, Mesulergine, BF-1 , LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**"
16. The method of claim 15, wherein the pimavanserin is administered in an amount of 1-100 mg.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein **R1 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl;

	wherein **R2 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R3 is** selected from the group consisting of **hydrogen**, methoxy, methyl, hydroxy and a halogen; and wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy; wherein **R5 is** selected from the group consisting of **deuterium (2H) and protium (1H)**; **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **claim 3** "The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula (I)** is selected from the group consisting of **N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N-diethyltryptamine, N,N-dipropyltryptamine and N,N-diisopropyltryptamine.**" From **claim 4** "The **combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is** selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, **Pimavanserin**, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK-215083, Cyamemazine, Mesulergine, BF-1 , LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**" From **page 29** "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise **0.5 -1000 mg of a compound described by formula (I)** and/or **0.5 - 1000 mg of a 5-HT2A receptor antagonist**."

	8. FDA (2016) "NUPLAZID (PIMAVANSERIN): HIGHLIGHTS OF PRESCRIBING INFORMATION" URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf From **page 1** "DOSAGE AND ADMINISTRATION: Recommended dose is 34 mg, taken orally as two 17 mg tablets once daily, without titration."
17. The method of claim 9, wherein the psychedelic drug and duration shortening agent are in dosage units chosen from the group consisting of separate dosage units, in the same dosage unit with the same release profiles, and in the same dosage unit with different release profiles.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein **R1 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R2 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R3 is** selected from the group consisting of **hydrogen**, methoxy, methyl, hydroxy and a halogen; and wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy;

	wherein **R5 is** selected from the group consisting of **deuterium (2H) and protium (1H)**; **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**" From **page 15** "The term "combination product' can refer to **(i) a product comprised of two or more regulated components that are physically, chemically, or otherwise combined or mixed and produced as a single entity**; (ii) two or more separate products packaged together in a single package or as a unit and comprised of drug and device products, device and biological products, or biological and drug products; (iii) a drug, device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device, or biological product where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose; or (iv) any investigational drug, device, or biological product packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device, or biological product where both are required to achieve the intended use, indication, or effect."
18. The method of claim 9, further including the step of reducing the time of subjective effects or/and reducing the amount of effects including any drug effect, bad drug effect, anxiety, ego-dissolution, and autonomic response measures by 10-100% compared with a treatment of the same	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:

amount of the psychedelic drug alone.	 wherein **R1 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R2 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R3 is** selected from the group consisting of **hydrogen**, methoxy, methyl, hydroxy and a halogen; and wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy; wherein **R5 is** selected from the group consisting of **deuterium (2H) and protium (1H)**; **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**"
19. The method of claim 9, further providing no recurrence of the psychedelic drug effects after the	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:

duration shortening agent is administered.	 wherein **R1 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R2 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R3 is** selected from the group consisting of **hydrogen**, methoxy, methyl, hydroxy and a halogen; and wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy; wherein **R5 is** selected from the group consisting of **deuterium (2H) and protium (1H)**; **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**"
20. The method of claim 9, further including a step chosen from the group consisting of reducing time and/or degree of	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:

cognitive impairment due to the psychedelic drug, reducing time of treatment session supervision by medical personnel, reducing intensity and/or duration of anxiety or any other acute adverse effects in response to the psychedelic drug, reducing expected acute adverse effects intensity and/or duration due to inadvertent administration of a high dose of the psychedelic drug, reducing expected acute adverse effects intensity and/or duration due to intentional intake of the psychedelic drug, and reducing expected acute adverse effects duration and/or intensity due to intentional intake of the psychedelic drug in doses considered too high or producing too strong effects after administration.	 wherein **R1 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R2 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R3 is** selected from the group consisting of **hydrogen**, methoxy, methyl, hydroxy and a halogen; and wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy; wherein **R5 is** selected from the group consisting of **deuterium (2H) and protium (1H)**; **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**" From **page 14** "The terms **"hallucinogenic side effects" and "psychedelic side effects" are used in the present** application interchangeably to refer to unwanted and/or unintended secondary effects caused by the administration of a medicament to an individual resulting in **subjective experiences being qualitatively different from those of ordinary consciousness**. These experiences can include derealization, depersonalization,

	hallucinations and/or sensory distortions in the visual, auditory, olfactory, tactile, proprioceptive and/or interoceptive spheres and/or any other perceptual modifications, and/or **any other substantial subjective changes in cognition, memory, emotion and consciousness.**"
21. A method of stopping the acute duration of action of a psychedelic drug in an individual, including the steps of: administering a duration shortening and/or effect reducing agent to the individual after the individual has taken a psychedelic drug; and stopping the acute effects of the psychedelic drug.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein **R1 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R2 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R3 is** selected from the group consisting of **hydrogen**, methoxy, methyl, hydroxy and a halogen; and wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy; wherein **R5 is** selected from the group consisting of **deuterium (2H) and protium (1H)**; **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament."

From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**"

From **page 32** "A compound described by **formula (I) and a 5-HT2A receptor antagonist may be administered together or separately** to an individual who suffers from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders.

From **page 32** "In a preferred embodiment, a compound described by formula (I) may be administered to an individual who is already being administered a 5-HT2A receptor antagonist and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders. Conversely, in an alternative embodiment, **a 5-HT2A receptor antagonist may be administered to an individual who is already being administered a compound described by formula (I)** and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders."

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit."

7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL:

	https://web.archive.org/web/20200928082744/https://www.psychedelicpassage.com/psychedelic-dosage-guide-how-much-of-each-substance-to-take/ "Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 – 150 µg (micrograms) per individual, 200+ µg in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 µg per tab**." 4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109 From **paragraph 5** "**Quetiapine has antagonist actions at 5-HT2A receptors**, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
22. The method of claim 21, wherein the individual is experiencing an adverse effect due to the psychedelic drug.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein **R1 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl;

	wherein **R2 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R3 is** selected from the group consisting of **hydrogen**, methoxy, methyl, hydroxy and a halogen; and wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy; wherein **R5 is** selected from the group consisting of **deuterium (2H) and protium (1H)**; **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**" From **page 32** "A compound described by **formula (I) and a 5-HT2A receptor antagonist may be administered together or separately** to an individual who suffers from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders. From **page 32** "In a preferred embodiment, a compound described by formula (I) may be administered to an individual who is already being administered a 5-HT2A receptor antagonist and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders. Conversely, in an alternative embodiment, **a 5-HT2A receptor antagonist may be administered to an individual who is already being administered a compound described by formula (I)** and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders." From **page 14** "The terms **"hallucinogenic side effects" and "psychedelic side effects" are used in the present** application interchangeably to **refer to unwanted and/or unintended secondary effects** caused by the administration of a medicament to an individual resulting in **subjective experiences being qualitatively different from those of ordinary consciousness**.

	These experiences can include derealization, depersonalization, hallucinations and/or sensory distortions in the visual, auditory, olfactory, tactile, proprioceptive and/or interoceptive spheres and/or any other perceptual modifications, and/or **any other substantial subjective changes in cognition, memory, emotion and consciousness.**" 3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844  From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, **I would recommend it to anyone, at least to have as part of a psychedelic crisis kit**." 7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psychedelicpassage.com/psychedelic-dosage-guide-how-much-of-each-substance-to-take/ "Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 – 150 µg (micrograms) per individual, 200+ µg in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 µg per tab**." 4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109 From **paragraph 5** "**Quetiapine has antagonist actions at 5-HT2A receptors**, one of the key properties of second-generation

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

	antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
23. The method of claim 21, wherein the individual has overdosed on the psychedelic drug.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein **R1 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R2 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R3 is** selected from the group consisting of **hydrogen**, methoxy, methyl, hydroxy and a halogen; and wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy; wherein **R5 is** selected from the group consisting of **deuterium (2H) and protium (1H)**; **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **claim 4** "The **combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is** selected from the group consisting of Methiothepin, Ritanserin,

	Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, **Pimavanserin**, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK-215083, Cyamemazine, Mesulergine, BF-1 , LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**" From **page 29** "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise **0.5 -1000 mg of a compound described by formula (I)** and/or **0.5 - 1000 mg of a 5-HT2A receptor antagonist**." 3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844  DOSE: T+ 0:00 | 1 hit | oral | LSD | (blotter / tab) T+ 2:00 | 66 mg | oral | Pharms - Quetiapine | (pill / tablet) T+ 3:00 | 33 mg | oral | Pharms - Quetiapine | (pill / tablet) T+ 4:00 | 200 mg | oral | Pharms - Ibuprofen | T+ 6:30 | 1 glass | oral | Alcohol - Beer/Wine | From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit." 7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psychedelicpassage.com/psychedelic-dosage-guide-how-much-of-each-substance-to-take/

	"Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 – 150 µg (micrograms) per individual, 200+ µg in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 µg per tab**." 4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109 From **paragraph 5** "**Quetiapine has antagonist actions at 5-HT2A receptors**, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
24. The method of claim 21, wherein the duration shortening agent is administered 1 minute to 24 hours after administering the psychedelic drug.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein **R1 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R2 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R3 is** selected from the group consisting of **hydrogen**, methoxy, methyl, hydroxy and a halogen; and

	wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy; wherein **R5 is** selected from the group consisting of **deuterium (2H) and protium (1H)**; **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**" From **page 32** "A compound described by **formula (I) and a 5-HT2A receptor antagonist may be administered together or separately** to an individual who suffers from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders. From **page 32** "In a preferred embodiment, a compound described by formula (I) may be administered to an individual who is already being administered a 5-HT2A receptor antagonist and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders. Conversely, in an alternative embodiment, **a 5-HT2A receptor antagonist may be administered to an individual who is already being administered a compound described by formula (I)** and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders." 3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

	 From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit." 7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psychedelicpassage.com/psychedelic-dosage-guide-how-much-of-each-substance-to-take/ "Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 – 150 µg (micrograms) per individual, 200+ µg in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 µg per tab**." 4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109 From **paragraph 5** "**Quetiapine has antagonist actions at 5-HT2A receptors**, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
25. The method of claim 21, wherein the psychedelic drug is a 5HT2A agonist chosen from the group consisting of LSD, psilocybin, psilocin, mescaline, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT),	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:

dimethyltryptamine (DMT), 2,5-dimethoxy-4-iodoamphetamine (DOI), 2,5-dimethoxy-4-bromoamphetamie (DOB), salts thereof, tartrates thereof, solvates thereof, isomers thereof, deuterated forms thereof, analogs thereof, and homologues thereof.	 wherein **R1 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R2 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R3 is** selected from the group consisting of **hydrogen**, methoxy, methyl, hydroxy and a halogen; and wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy; wherein **R5 is** selected from the group consisting of **deuterium (2H) and protium (1H)**; **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**" From **page 32** "A compound described by **formula (I) and a 5-HT2A receptor antagonist may be administered together or separately** to an individual who suffers from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders.

From **page 32** “In a preferred embodiment, a compound described by formula (I) may be administered to an individual who is already being administered a 5-HT2A receptor antagonist and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders. Conversely, in an alternative embodiment, **a 5-HT2A receptor antagonist may be administered to an individual who is already being administered a compound described by formula (I)** and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders.”

From **claim 3** “The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula (I)** is selected from the group consisting of **N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N-diethyltryptamine, N,N-dipropyltryptamine and N,N-diisopropyltryptamine.**”

3. PHARMBOY (2013) “Cheating Hofmann - LSD, Quetiapine & Alcohol” Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844



DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 25** “Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit.”

7. LEVICH (2020) “Psychedelic Dosage Guide: How Much of Each Substance to Take” Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psychedelicpassage.com/psychedelic-dosage-guide-how-much-of-each-substance-to-take/

	"Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 – 150 µg (micrograms) per individual, 200+ µg in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 µg per tab**." 4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109 From **paragraph 5** "**Quetiapine has antagonist actions at 5-HT2A receptors**, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
26. The method of claim 21, wherein the psychedelic drug is administered in an amount that provides an effect for at least 2 hours.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and

	wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy; wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **claim 3** "The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula (I)** is selected from the group consisting of **N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N-diethyltryptamine, N,N-dipropyltryptamine and N,N-diisopropyltryptamine.**" From **page 29** "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise **0.5 -1000 mg of a compound described by formula (I)** and/or 0.5 - 1000 mg of a 5-HT2A receptor antagonist." 2. VALERIANI (2015) "Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms" Human Psychopharmacology: Clinical and Experimental. 30:249-254. From **page 250** "In most cases, users reported here to **ingest olanzapine at relatively small dosages, usually ranging from 5 to 10 mg** once a day for just a few days **as a "terminator"/"modulator" of unwanted NPS psychedelic effects**." From **page 251** "Most online reports about olanzapine were here related to its use as a short-term, self-prescribed treatment for the psychedelic crises/"bad trips." **Symptoms of psychedelic crises usually last a few hours, depending on the drug taken and dose ingested (Mangot, 2013). Indeed, SC's effects may last 1–4 h (Hoyte et al., 2012); tryptamines' effects 2–6 h (Hallock et al., 2013); lysergic acid diethylamide [LSD] 6–14 h (Krebs and Johansen, 2013); and mescaline 8–16 h (Trachsel, 2012)**."

From **page 251** “There are already published data showing the effectiveness of olanzapine and, in general, of second-generation antipsychotics (SGA), as first-line treatments in psychotic disorders induced by drugs such as cannabis (Bersani et al., 2002a, 2002b; Sevy et al., 2011) and cocaine (Testa et al., 2013). Compared with first-generation antipsychotics (FGA), SGA may present with some advantages while treating drug-induced psychosis, including the following: (i) SGA induce fewer/no extrapyramidal symptoms (Ohno et al., 2013); (ii) SGA quickly dissociate from D2 receptors, unlike FGA/haloperidol, and hence may seem to be less associated with dysphoria and interference with drug reward anticipation/craving (Juckel et al., 2006); (iii) SGA seem more effective in the treatment of negative symptoms (Buchanan et al., 2005), alter positively mood (McIntyre et al., 2004), and have a positive impact on cognition (Bersani et al., 2011); and (iv) **SGA act as antagonists of 5HT2A receptor, which is the main target of most hallucinogenic drugs** (Potvin et al., 2003). From this point of view, **both clozapine and olanzapine may present with a distinct advantage in reducing drug-induced psychotic symptoms** (Murthy and Chand, 2012).”

3. PHARMBOY (2013) “Cheating Hofmann - LSD, Quetiapine & Alcohol” Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 25** “Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit.”

7. LEVICH (2020) “Psychedelic Dosage Guide: How Much of Each Substance to Take” Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psychedelicpassage.com/psychedelic-dosage-guide-how-much-of-each-substance-to-take/

	"Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 – 150 µg (micrograms) per individual, 200+ µg in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 µg per tab**." 4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109 From **paragraph 5** "**Quetiapine has antagonist actions at 5-HT2A receptors**, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
27. The method of claim 25, wherein the psychedelic drug is administered in an amount chosen from the group consisting of 0.01-1 mg LSD, 10-50 mg psilocybin, 100-800 mg mescaline, 20-100 mg DMT, 0.1-5 mg DOI, and 0.1-5 mg DOB.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;

	wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy; wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **claim 3** "The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula (I)** is selected from the group consisting of **N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N-diethyltryptamine, N,N-dipropyltryptamine and N,N-diisopropyltryptamine.**" From **page 29** "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise **0.5 -1000 mg of a compound described by formula (I)** and/or 0.5 - 1000 mg of a 5-HT2A receptor antagonist." 2. VALERIANI (2015) "Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms" Human Psychopharmacology: Clinical and Experimental. 30:249-254. From **page 250** "In most cases, users reported here to **ingest olanzapine at relatively small dosages, usually ranging from 5 to 10 mg** once a day for just a few days **as a "terminator"/"modulator" of unwanted NPS psychedelic effects**." From **page 251** "Most online reports about olanzapine were here related to its use as a short-term, self-prescribed treatment for the psychedelic crises/"bad trips." **Symptoms of psychedelic crises usually last a few hours, depending on the drug taken and dose ingested (Mangot, 2013). Indeed, SC's effects may last 1–4 h (Hoyte et al., 2012); tryptamines' effects 2–6 h (Hallock et al., 2013); lysergic acid diethylamide [LSD] 6–14 h (Krebs and Johansen, 2013); and mescaline 8–16 h (Trachsel, 2012)**."

From **page 251** “There are already published data showing the effectiveness of olanzapine and, in general, of second-generation antipsychotics (SGA), as first-line treatments in psychotic disorders induced by drugs such as cannabis (Bersani et al., 2002a, 2002b; Sevy et al., 2011) and cocaine (Testa et al., 2013). Compared with first-generation antipsychotics (FGA), SGA may present with some advantages while treating drug-induced psychosis, including the following: (i) SGA induce fewer/no extrapyramidal symptoms (Ohno et al., 2013); (ii) SGA quickly dissociate from D2 receptors, unlike FGA/haloperidol, and hence may seem to be less associated with dysphoria and interference with drug reward anticipation/craving (Juckel et al., 2006); (iii) SGA seem more effective in the treatment of negative symptoms (Buchanan et al., 2005), alter positively mood (McIntyre et al., 2004), and have a positive impact on cognition (Bersani et al., 2011); and (iv) **SGA act as antagonists of 5HT2A receptor, which is the main target of most hallucinogenic drugs** (Potvin et al., 2003). From this point of view, **both clozapine and olanzapine may present with a distinct advantage in reducing drug-induced psychotic symptoms** (Murthy and Chand, 2012).”

3. PHARMBOY (2013) “Cheating Hofmann - LSD, Quetiapine & Alcohol” Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844



DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 25** “Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit.”

7. LEVICH (2020) “Psychedelic Dosage Guide: How Much of Each Substance to Take” Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psychedelicpassage.com/psychedelic-dosage-guide-how-much-of-each-substance-to-take/

	"Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 – 150 µg (micrograms) per individual, 200+ µg in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 µg per tab**." 4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109 From **paragraph 5** "**Quetiapine has antagonist actions at 5-HT2A receptors**, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
28. The method of claim 21, wherein the duration shortening agent is a 5HT2A receptor antagonist.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and

	wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy; wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**"
29. The method of claim 28, wherein the duration shortening agent is chosen from the group consisting of pimavanserin, salts thereof, analogs thereof, and homologs thereof.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and

	wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy; wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **claim 3** "The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula (I)** is selected from the group consisting of **N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N-diethyltryptamine, N,N-dipropyltryptamine and N,N-diisopropyltryptamine.**" From **claim 4** "The **combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is** selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, **Pimavanserin**, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK-215083, Cyamemazine, Mesulergine, BF-1 , LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**"
30. The method of claim 29, wherein the pimavanserin is administered in an amount of 1-100 mg.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:



wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;

wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;

wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and

wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;

wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); **and**

(ii) a 5-HT2A receptor antagonist;

for use as a medicament."

From **claim 3** "The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula (I)** is selected from the group consisting of **N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N-diethyltryptamine, N,N-dipropyltryptamine and N,N-diisopropyltryptamine.**"

From **claim 4** "The **combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is** selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine,

	Agomelatine, **Pimavanserin**, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK-215083, Cyamemazine, Mesulergine, BF-1 , LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150." From **page 29** "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise **0.5 -1000 mg of a compound described by formula (I)** and/or **0.5 - 1000 mg of a 5-HT2A receptor antagonist**." 8. FDA (2016) "NUPLAZID (PIMAVANSERIN): HIGHLIGHTS OF PRESCRIBING INFORMATION" URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf From **page 1** "DOSAGE AND ADMINISTRATION: **Recommended dose is 34 mg**, taken orally as two 17 mg tablets once daily, without titration."
31. The method of claim 21, further providing no recurrence of the psychedelic drug effects after the duration shortening agent is administered.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**: 

	wherein **R1 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R2 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R3 is** selected from the group consisting of **hydrogen**, methoxy, methyl, hydroxy and a halogen; and wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy; wherein **R5 is** selected from the group consisting of **deuterium (2H) and protium (1H)**; **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**"
32. A method of stopping psychosis due to psychedelic administration, including the steps of: administering a duration shortening agent to the individual after the individual has taken a psychedelic drug; and stopping psychosis caused by the psychedelic drug.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**: 

	wherein **R1 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R2 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R3 is** selected from the group consisting of **hydrogen**, methoxy, methyl, hydroxy and a halogen; and wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy; wherein **R5 is** selected from the group consisting of **deuterium (2H) and protium (1H)**; **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**" From **page 14** "The terms **"hallucinogenic side effects" and "psychedelic side effects" are used in the present** application interchangeably to **refer to unwanted and/or unintended secondary effects** caused by the administration of a medicament to an individual resulting in **subjective experiences being qualitatively different from those of ordinary consciousness**. These experiences can include derealization, depersonalization, hallucinations and/or sensory distortions in the visual, auditory, olfactory, tactile, proprioceptive and/or interoceptive spheres and/or any other perceptual modifications, and/or **any other substantial subjective changes in cognition, memory, emotion and consciousness.**" 9. NIMH (2021) "Understanding Psychosis" Retrieved 13 May 2021. URL: https://web.archive.org/web/20210503133654/https://www.nimh.nih.gov/health/publications/understanding-psychosis/ "The word psychosis is used to describe conditions that affect the mind, **where there has been some loss of contact with reality**."

	"**Symptoms of psychosis include delusions (false beliefs) and hallucinations (seeing or hearing things that others do not see or hear). Other symptoms include incoherent or nonsense speech and behavior that is inappropriate for the situation**. A person in a psychotic episode also may experience depression, anxiety, sleep problems, social withdrawal, lack of motivation, and difficulty functioning overall." 3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844  From **paragraph 12** "Visualizations began at around 10:30 with crawling carpeting and changes in color hues. I felt as if my head was being detached from the rest of my body. Looking outside I noticed the color of the tree outside our home was leaning closer and closer to the window." From **paragraph 12** "By around 10:45 - 11:00, the peak is in full swing and I am melting into the floor, **getting very intense, hard to see, my visual field is sideways and standing up straight becomes hard**. Wow, this is really good acid. **Maybe too good, I thought, this is only the beginning, time to cut this short**." From **paragraph 13** "At 11:30 (or thereabouts) I consumed approx. 66mg of the Quetiapine." From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit **cutting the LSD short**) from the psychedelic aspect of my trip using the Seroquel, **I would recommend it to anyone, at least to have as part of a psychedelic crisis kit.**" 7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psychedelicpassage.com/psychedelic-dosage-guide-how-much-of-each-substance-to-take/

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

	"Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 – 150 µg (micrograms) per individual, 200+ µg in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 µg per tab**." 4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109 From **paragraph 5** "**Quetiapine has antagonist actions at 5-HT2A receptors**, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
33. The method of claim 32, wherein said stopping step further includes stopping or reducing a symptom chosen from the group consisting of delusions, hallucinations, talking incoherently, and agitation.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein **R1 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R2 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl;

	wherein **R3 is** selected from the group consisting of **hydrogen**, methoxy, methyl, hydroxy and a halogen; and wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy; wherein **R5 is** selected from the group consisting of **deuterium (2H) and protium (1H)**; **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**" From **page 14** "The terms **"hallucinogenic side effects" and "psychedelic side effects" are used in the present** application interchangeably to **refer to unwanted and/or unintended secondary effects** caused by the administration of a medicament to an individual resulting in **subjective experiences being qualitatively different from those of ordinary consciousness**. These experiences can include derealization, depersonalization, **hallucinations** and/or sensory distortions in the visual, auditory, olfactory, tactile, proprioceptive and/or interoceptive spheres and/or any other perceptual modifications, and/or any other substantial **subjective changes in cognition, memory, emotion and consciousness**." 9. NIMH (2021) "Understanding Psychosis" Retrieved 13 May 2021. URL: https://web.archive.org/web/20210503133654/https://www.nimh.nih.gov/health/publications/understanding-psychosis/ "The word psychosis is used to describe conditions that affect the mind, **where there has been some loss of contact with reality**." "**Symptoms of psychosis include delusions (false beliefs) and hallucinations (seeing or hearing things that others do not see or hear). Other symptoms include incoherent or nonsense speech and behavior that is inappropriate for the situation**. A person in a psychotic episode also may experience depression, anxiety, sleep problems, social withdrawal, lack of motivation, and difficulty functioning overall."

3. PHARMBOY (2013) “Cheating Hofmann - LSD, Quetiapine & Alcohol” Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 12** “Visualizations began at around 10:30 with crawling carpeting and changes in color hues. I felt as if my head was being detached from the rest of my body. Looking outside I noticed the color of the tree outside our home was leaning closer and closer to the window.”

From **paragraph 12** “By around 10:45 - 11:00, the peak is in full swing and I am melting into the floor, **getting very intense, hard to see, my visual field is sideways and standing up straight becomes hard**. Wow, this is really good acid. **Maybe too good, I thought, this is only the beginning, time to cut this short**.”

From **paragraph 13** “At 11:30 (or thereabouts) I consumed approx. 66mg of the Quetiapine.”

From **paragraph 25** “Considering how easy and smooth it felt coming down (albeit **cutting the LSD short**) from the psychedelic aspect of my trip using the Seroquel, **I would recommend it to anyone, at least to have as part of a psychedelic crisis kit.**”

7. LEVICH (2020) “Psychedelic Dosage Guide: How Much of Each Substance to Take” Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psychedelicpassage.com/psychedelic-dosage-guide-how-much-of-each-substance-to-take/

“Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 – 150 µg (micrograms) per individual, 200+ µg in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 µg per tab**.”

	4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109 From **paragraph 5** "**Quetiapine has antagonist actions at 5-HT2A receptors**, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
34. The method of claim 32, wherein the duration shortening agent is administered 1 minute to 24 hours after administering the psychedelic drug.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein **R1 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R2 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R3 is** selected from the group consisting of **hydrogen**, methoxy, methyl, hydroxy and a halogen; and wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy; wherein **R5 is** selected from the group consisting of **deuterium (2H) and protium (1H)**; **and**

	(ii) a 5-HT2A receptor antagonist; for use as a medicament." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**" From **page 32** "A compound described by **formula (I) and a 5-HT2A receptor antagonist may be administered together or separately** to an individual who suffers from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders. From **page 32** "In a preferred embodiment, a compound described by formula (I) may be administered to an individual who is already being administered a 5-HT2A receptor antagonist and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders. Conversely, in an alternative embodiment, **a 5-HT2A receptor antagonist may be administered to an individual who is already being administered a compound described by formula (I)** and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders." From **page 14** "The terms **"hallucinogenic side effects" and "psychedelic side effects" are used in the present** application interchangeably to **refer to unwanted and/or unintended secondary effects** caused by the administration of a medicament to an individual resulting in **subjective experiences being qualitatively different from those of ordinary consciousness**. These experiences can include derealization, depersonalization, **hallucinations** and/or sensory distortions in the visual, auditory, olfactory, tactile, proprioceptive and/or interoceptive spheres and/or any other perceptual modifications, and/or any other substantial **subjective changes in cognition, memory, emotion and consciousness**." 9. NIMH (2021) "Understanding Psychosis" Retrieved 13 May 2021. URL:

	https://web.archive.org/web/20210503133654/https://www.nimh.nih.gov/health/publications/understanding-psychosis/ "The word psychosis is used to describe conditions that affect the mind, **where there has been some loss of contact with reality**." "**Symptoms of psychosis include delusions (false beliefs) and hallucinations (seeing or hearing things that others do not see or hear). Other symptoms include incoherent or nonsense speech and behavior that is inappropriate for the situation**. A person in a psychotic episode also may experience depression, anxiety, sleep problems, social withdrawal, lack of motivation, and difficulty functioning overall." 3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844  From **paragraph 12** "Visualizations began at around 10:30 with crawling carpeting and changes in color hues. I felt as if my head was being detached from the rest of my body. Looking outside I noticed the color of the tree outside our home was leaning closer and closer to the window." From **paragraph 12** "By around 10:45 - 11:00, the peak is in full swing and I am melting into the floor, **getting very intense, hard to see, my visual field is sideways and standing up straight becomes hard**. Wow, this is really good acid. **Maybe too good, I thought, this is only the beginning, time to cut this short**." From **paragraph 13** "At 11:30 (or thereabouts) I consumed approx. 66mg of the Quetiapine." From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit **cutting the LSD short**) from the psychedelic aspect of my trip using the Seroquel, **I would recommend it to anyone, at least to have as part of a psychedelic crisis kit.**"

	7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psychedelicpassage.com/psychedelic-dosage-guide-how-much-of-each-substance-to-take/ "Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 – 150 µg (micrograms) per individual, 200+ µg in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 µg per tab**." 4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109 From **paragraph 5** "**Quetiapine has antagonist actions at 5-HT2A receptors**, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
35. The method of claim 32, wherein the psychedelic drug is a 5HT2A agonist chosen from the group consisting of LSD, psilocybin, psilocin, mescaline, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), dimethyltryptamine (DMT), 2,5-dimethoxy-4-iodoamphetamine (DOI), 2,5-dimethoxy-4-bromoamphetamie (DOB), salts thereof, tartrates thereof, solvates thereof, isomers thereof, deuterated forms thereof, analogs	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**: 

thereof, and homologues thereof.	wherein **R1 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R2 is** selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl; wherein **R3 is** selected from the group consisting of **hydrogen**, methoxy, methyl, hydroxy and a halogen; and wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy; wherein **R5 is** selected from the group consisting of **deuterium (2H) and protium (1H)**; **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **claim 3** "The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula (I)** is selected from the group consisting of **N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N-diethyltryptamine, N,N-dipropyltryptamine and N,N-diisopropyltryptamine.**" From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**" From **page 32** "A compound described by **formula (I) and a 5-HT2A receptor antagonist may be administered together or separately** to an individual who suffers from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders. From **page 32** "In a preferred embodiment, a compound described by formula (I) may be administered to an individual who is already being administered a 5-HT2A receptor antagonist and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders. Conversely, in an alternative embodiment, **a 5-HT2A receptor antagonist may be administered to an individual who is already being administered a compound described by formula (I)** and who is suffering from one or more

psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders."

From **page 14** "The terms **"hallucinogenic side effects" and "psychedelic side effects" are used in the present** application interchangeably to **refer to unwanted and/or unintended secondary effects** caused by the administration of a medicament to an individual resulting in **subjective experiences being qualitatively different from those of ordinary consciousness**. These experiences can include derealization, depersonalization, **hallucinations** and/or sensory distortions in the visual, auditory, olfactory, tactile, proprioceptive and/or interoceptive spheres and/or any other perceptual modifications, and/or any other substantial **subjective changes in cognition, memory, emotion and consciousness**."

9. NIMH (2021) "Understanding Psychosis" Retrieved 13 May 2021. URL: https://web.archive.org/web/20210503133654/https://www.nimh.nih.gov/health/publications/understanding-psychosis/

"The word psychosis is used to describe conditions that affect the mind, **where there has been some loss of contact with reality**."

"**Symptoms of psychosis include delusions (false beliefs) and hallucinations (seeing or hearing things that others do not see or hear). Other symptoms include incoherent or nonsense speech and behavior that is inappropriate for the situation**. A person in a psychotic episode also may experience depression, anxiety, sleep problems, social withdrawal, lack of motivation, and difficulty functioning overall."

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

	From **paragraph 12** "Visualizations began at around 10:30 with crawling carpeting and changes in color hues. I felt as if my head was being detached from the rest of my body. Looking outside I noticed the color of the tree outside our home was leaning closer and closer to the window." From **paragraph 12** "By around 10:45 - 11:00, the peak is in full swing and I am melting into the floor, **getting very intense, hard to see, my visual field is sideways and standing up straight becomes hard**. Wow, this is really good acid. **Maybe too good, I thought, this is only the beginning, time to cut this short**." From **paragraph 13** "At 11:30 (or thereabouts) I consumed approx. 66mg of the Quetiapine." From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit **cutting the LSD short**) from the psychedelic aspect of my trip using the Seroquel, **I would recommend it to anyone, at least to have as part of a psychedelic crisis kit.**" 7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psychedelicpassage.com/psychedelic-dosage-guide-how-much-of-each-substance-to-take/ "Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 – 150 µg (micrograms) per individual, 200+ µg in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 µg per tab**." 4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109 From **paragraph 5** "**Quetiapine has antagonist actions at 5-HT2A receptors**, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
36. The method of claim 32, wherein the psychedelic drug is	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)

administered in an amount that provides an effect for at least 2 hours.	From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy; wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **claim 3** "The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula (I)** is selected from the group consisting of **N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N-diethyltryptamine, N,N-dipropyltryptamine and N,N-diisopropyltryptamine.**" From **claim 4** "The **combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is**

	selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, **Pimavanserin**, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK-215083, Cyamemazine, Mesulergine, BF-1 , LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**" From **page 14** "The terms **"hallucinogenic side effects" and "psychedelic side effects" are used in the present** application interchangeably to **refer to unwanted and/or unintended secondary effects** caused by the administration of a medicament to an individual resulting in **subjective experiences being qualitatively different from those of ordinary consciousness**. These experiences can include derealization, depersonalization, **hallucinations** and/or sensory distortions in the visual, auditory, olfactory, tactile, proprioceptive and/or interoceptive spheres and/or any other perceptual modifications, and/or any other substantial **subjective changes in cognition, memory, emotion and consciousness**." From **page 29** "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise **0.5 -1000 mg of a compound described by formula (I)** and/or 0.5 - 1000 mg of a 5-HT2A receptor antagonist." 9. NIMH (2021) "Understanding Psychosis" Retrieved 13 May 2021. URL: https://web.archive.org/web/20210503133654/https://www.nimh.nih.gov/health/publications/understanding-psychosis/ "The word psychosis is used to describe conditions that affect the mind, **where there has been some loss of contact with reality**." "**Symptoms of psychosis include delusions (false beliefs) and hallucinations (seeing or hearing things that others do not see or**

	hear). Other symptoms include incoherent or nonsense speech and behavior that is inappropriate for the situation. A person in a psychotic episode also may experience depression, anxiety, sleep problems, social withdrawal, lack of motivation, and difficulty functioning overall." 3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844  From **paragraph 12** "Visualizations began at around 10:30 with crawling carpeting and changes in color hues. I felt as if my head was being detached from the rest of my body. Looking outside I noticed the color of the tree outside our home was leaning closer and closer to the window." From **paragraph 12** "By around 10:45 - 11:00, the peak is in full swing and I am melting into the floor, **getting very intense, hard to see, my visual field is sideways and standing up straight becomes hard**. Wow, this is really good acid. **Maybe too good, I thought, this is only the beginning, time to cut this short**." From **paragraph 13** "At 11:30 (or thereabouts) I consumed approx. 66mg of the Quetiapine." From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit **cutting the LSD short**) from the psychedelic aspect of my trip using the Seroquel, **I would recommend it to anyone, at least to have as part of a psychedelic crisis kit.**" 7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psychedelicpassage.com/psychedelic-dosage-guide-how-much-of-each-substance-to-take/

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

	"Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 – 150 µg (micrograms) per individual, 200+ µg in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 µg per tab**." 4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109 From **paragraph 5** "**Quetiapine has antagonist actions at 5-HT2A receptors**, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
37. The method of claim 35, wherein the psychedelic drug is administered in an amount chosen from the group consisting of 0.01-1 mg LSD, 10-50 mg psilocybin, 100-800 mg mescaline, 20-100 mg DMT, 0.1-5 mg DOI, and 0.1-5 mg DOB.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and

	wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy; wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **claim 3** "The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula (I)** is selected from the group consisting of **N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N-diethyltryptamine, N,N-dipropyltryptamine and N,N-diisopropyltryptamine.**" From **claim 4** "The **combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is** selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, **Pimavanserin**, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK-215083, Cyamemazine, Mesulergine, BF-1 , LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**" From **page 14** "The terms **"hallucinogenic side effects" and "psychedelic side effects" are used in the present** application interchangeably to **refer to unwanted and/or unintended secondary effects** caused by the administration of a medicament to an individual resulting in **subjective experiences being qualitatively different from those of ordinary consciousness**. These experiences can include derealization, depersonalization, **hallucinations** and/or sensory distortions in the visual, auditory, olfactory, tactile, proprioceptive and/or interoceptive spheres and/or any other perceptual modifications, and/or any other substantial

	subjective changes in cognition, memory, emotion and consciousness." From **page 29** "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise **0.5 -1000 mg of a compound described by formula (I)** and/or 0.5 - 1000 mg of a 5-HT2A receptor antagonist." 9. NIMH (2021) "Understanding Psychosis" Retrieved 13 May 2021. URL: https://web.archive.org/web/20210503133654/https://www.nimh.nih.gov/health/publications/understanding-psychosis/ "The word psychosis is used to describe conditions that affect the mind, **where there has been some loss of contact with reality**." "**Symptoms of psychosis include delusions (false beliefs) and hallucinations (seeing or hearing things that others do not see or hear). Other symptoms include incoherent or nonsense speech and behavior that is inappropriate for the situation**. A person in a psychotic episode also may experience depression, anxiety, sleep problems, social withdrawal, lack of motivation, and difficulty functioning overall." 3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844  From **paragraph 12** "Visualizations began at around 10:30 with crawling carpeting and changes in color hues. I felt as if my head was being detached from the rest of my body. Looking outside I noticed the color of the tree outside our home was leaning closer and closer to the window." From **paragraph 12** "By around 10:45 - 11:00, the peak is in full swing and I am melting into the floor, **getting very intense, hard to**

	see, my visual field is sideways and standing up straight becomes hard. Wow, this is really good acid. **Maybe too good, I thought, this is only the beginning, time to cut this short**." From **paragraph 13** "At 11:30 (or thereabouts) I consumed approx. 66mg of the Quetiapine." From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit **cutting the LSD short**) from the psychedelic aspect of my trip using the Seroquel, **I would recommend it to anyone, at least to have as part of a psychedelic crisis kit.**" 7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psychedelicpassage.com/psychedelic-dosage-guide-how-much-of-each-substance-to-take/ "Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 – 150 µg (micrograms) per individual, 200+ µg in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 µg per tab**." 4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109 From **paragraph 5** "**Quetiapine has antagonist actions at 5-HT2A receptors**, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
38. The method of claim 32, wherein the duration shortening agent is a 5HT2A receptor antagonist.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:



wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;

wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;

wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and

wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;

wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); **and**

(ii) a 5-HT2A receptor antagonist;

for use as a medicament."

From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**"

From **page 14** "The terms **"hallucinogenic side effects" and "psychedelic side effects" are used in the present** application interchangeably to **refer to unwanted and/or unintended secondary effects** caused by the administration of a medicament to an individual resulting in **subjective experiences being qualitatively different from those of ordinary consciousness**. These experiences can include derealization, depersonalization,

	hallucinations and/or sensory distortions in the visual, auditory, olfactory, tactile, proprioceptive and/or interoceptive spheres and/or any other perceptual modifications, and/or any other substantial **subjective changes in cognition, memory, emotion and consciousness**." 9. NIMH (2021) "Understanding Psychosis" Retrieved 13 May 2021. URL: https://web.archive.org/web/20210503133654/https://www.nimh.nih.gov/health/publications/understanding-psychosis/ "The word psychosis is used to describe conditions that affect the mind, **where there has been some loss of contact with reality**." "**Symptoms of psychosis include delusions (false beliefs) and hallucinations (seeing or hearing things that others do not see or hear). Other symptoms include incoherent or nonsense speech and behavior that is inappropriate for the situation**. A person in a psychotic episode also may experience depression, anxiety, sleep problems, social withdrawal, lack of motivation, and difficulty functioning overall." 3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844  From **paragraph 12** "Visualizations began at around 10:30 with crawling carpeting and changes in color hues. I felt as if my head was being detached from the rest of my body. Looking outside I noticed the color of the tree outside our home was leaning closer and closer to the window." From **paragraph 12** "By around 10:45 - 11:00, the peak is in full swing and I am melting into the floor, **getting very intense, hard to see, my visual field is sideways and standing up straight becomes hard**. Wow, this is really good acid. **Maybe too good, I thought, this is only the beginning, time to cut this short**."

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

	From **paragraph 13** "At 11:30 (or thereabouts) I consumed approx. 66mg of the Quetiapine." From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit **cutting the LSD short**) from the psychedelic aspect of my trip using the Seroquel, **I would recommend it to anyone, at least to have as part of a psychedelic crisis kit.**" 7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psychedelicpassage.com/psychedelic-dosage-guide-how-much-of-each-substance-to-take/ "Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 – 150 µg (micrograms) per individual, 200+ µg in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 µg per tab**." 4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109 From **paragraph 5** "**Quetiapine has antagonist actions at 5-HT2A receptors**, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
39. The method of claim 38, wherein the duration shortening agent is chosen from the group consisting of pimavanserin, salts thereof, analogs thereof, and homologs thereof.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:



wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;

wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;

wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and

wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;

wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); **and**

(ii) a 5-HT2A receptor antagonist;

for use as a medicament."

From **claim 4** "The **combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is** selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, **Pimavanserin**, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK-215083, Cyamemazine, Mesulergine, BF-1 , LY215840,

	Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**" From **page 14** "The terms **"hallucinogenic side effects" and "psychedelic side effects" are used in the present** application interchangeably to **refer to unwanted and/or unintended secondary effects** caused by the administration of a medicament to an individual resulting in **subjective experiences being qualitatively different from those of ordinary consciousness**. These experiences can include derealization, depersonalization, **hallucinations** and/or sensory distortions in the visual, auditory, olfactory, tactile, proprioceptive and/or interoceptive spheres and/or any other perceptual modifications, and/or any other substantial **subjective changes in cognition, memory, emotion and consciousness**."
40. The method of claim 39, wherein the pimavanserin is administered in an amount of 1-100 mg.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 1** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;

	wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy; wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); **and** **(ii) a 5-HT2A receptor antagonist**; for use as a medicament." From **claim 4** "The **combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is** selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, **Pimavanserin**, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK-215083, Cyamemazine, Mesulergine, BF-1 , LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**" From **page 14** "The terms **"hallucinogenic side effects" and "psychedelic side effects" are used in the present** application interchangeably to **refer to unwanted and/or unintended secondary effects** caused by the administration of a medicament to an individual resulting in **subjective experiences being qualitatively different from those of ordinary consciousness**. These experiences can include derealization, depersonalization, **hallucinations** and/or sensory distortions in the visual, auditory, olfactory, tactile, proprioceptive and/or interoceptive spheres and/or any other perceptual modifications, and/or any other substantial **subjective changes in cognition, memory, emotion and consciousness**."

	From **page 29** "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise **0.5 -1000 mg of a compound described by formula (I)** and/or **0.5 - 1000 mg of a 5-HT2A receptor antagonist**." 8. FDA (2016) "NUPLAZID (PIMAVANSERIN): HIGHLIGHTS OF PRESCRIBING INFORMATION" URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf From **page 1** "DOSAGE AND ADMINISTRATION: **Recommended dose is 34 mg**, taken orally as two 17 mg tablets once daily, without titration.
41. A method of stopping psychosis due to a substance or disease, including the steps of: administering a duration shortening agent to the individual caused by a substance or disease other than Parkinson's disease or schizophrenia; and stopping psychosis caused by the substance or disease.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 2** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and

	wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy; wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); **and** **(ii) a 5-HT2A receptor antagonist**; for use in the treatment and/or prevention of psychiatric and/or neurological disorders." From **claim 9** "The combination product according to anyone of claims 2-8 for use in the treatment and/or prevention of a disorder selected from the group consisting of acquired brain injury, ataxia, brain tumor, dementia, dystonia, epilepsy, functional and dissociative neurological symptoms, meningitis, motor neuron disease, multiple sclerosis, muscular dystrophy, myalgic encephalomyelitis, Parkinson's disease, progressive supranuclear palsy, Huntington's disease, Alzheimer's disease, fronto-temporal dementia, vascular dementia, cognitive decline associated with aging, spina bifida, hydrocephalus, spinal injury, stroke, Tourette syndrome, transverse myelitis, panic disorder, agoraphobia, social anxiety disorder, phobias, post-traumatic stress disorder, obsessive compulsive disorder, generalized anxiety disorder, bipolar disorder, depression, anorexia nervosa, binge eating disorder, bulimia nervosa, **psychosis**, schizophrenia, substance addiction and personality disorders." 2. VALERIANI (2015) "Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms" Human Psychopharmacology: Clinical and Experimental. 30:249-254. From **page 250** "In most cases, users reported here to **ingest olanzapine at relatively small dosages, usually ranging from 5 to 10 mg once a day for just a few days as a "terminator"/"modulator" of unwanted NPS psychedelic effects**." From **page 251** "**Most online reports about olanzapine were here related to its use as a short-term, self-prescribed treatment for the psychedelic crises/"bad trips."** Symptoms of psychedelic crises usually last a few hours, depending on the drug taken and dose ingested (Mangot, 2013). Indeed, SC's effects may last 1–4 h

	(Hoyte et al., 2012); tryptamines' effects 2–6 h (Hallock et al., 2013); lysergic acid diethylamide [LSD] 6–14 h (Krebs and Johansen, 2013); and mescaline 8–16 h (Trachsel, 2012)." From **page 251** "There are already published data showing the effectiveness of olanzapine and, in general, of **second-generation antipsychotics (SGA)**, as first-line treatments in psychotic disorders induced by drugs such as cannabis (Bersani et al., 2002a, 2002b; Sevy et al., 2011) and cocaine (Testa et al., 2013). **Compared with first-generation antipsychotics (FGA), SGA may present with some advantages while treating drug-induced psychosis**, including the following: (i) SGA induce fewer/no extrapyramidal symptoms (Ohno et al., 2013); (ii) SGA quickly dissociate from D2 receptors, unlike FGA/haloperidol, and hence may seem to be less associated with dysphoria and interference with drug reward anticipation/craving (Juckel et al., 2006); (iii) SGA seem more effective in the treatment of negative symptoms (Buchanan et al., 2005), alter positively mood (McIntyre et al., 2004), and have a positive impact on cognition (Bersani et al., 2011); and (iv) **SGA act as antagonists of 5HT2A receptor, which is the main target of most hallucinogenic drugs** (Potvin et al., 2003). From this point of view, **both clozapine and olanzapine may present with a distinct advantage in reducing drug-induced psychotic symptoms** (Murthy and Chand, 2012). 3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844  From **paragraph 12** "Visualizations began at around 10:30 with crawling carpeting and changes in color hues. I felt as if my head was being detached from the rest of my body. Looking outside I noticed the color of the tree outside our home was leaning closer and closer to the window." From **paragraph 12** "By around 10:45 - 11:00, the peak is in full swing and I am melting into the floor, **getting very intense, hard to see, my visual field is sideways and standing up straight**

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

	becomes hard. Wow, this is really good acid. **Maybe too good, I thought, this is only the beginning, time to cut this short**." From **paragraph 13** "At 11:30 (or thereabouts) I consumed approx. 66mg of the Quetiapine." From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit **cutting the LSD short**) from the psychedelic aspect of my trip using the Seroquel, **I would recommend it to anyone, at least to have as part of a psychedelic crisis kit.**" 7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psychedelicpassage.com/psychedelic-dosage-guide-how-much-of-each-substance-to-take/ "Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 – 150 µg (micrograms) per individual, 200+ µg in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 µg per tab**." 4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109 From **paragraph 5** "**Quetiapine has antagonist actions at 5-HT2A receptors**, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
42. The method of claim 41, wherein the disease is chosen from the group consisting of bipolar disorder, severe depression, severe stress, severe anxiety, HIV, AIDS, malaria, syphilis, hypoglycemia, lupus, multiple sclerosis, and brain tumors.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 2** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:



wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;

wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;

wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and

wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;

wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); **and**

(ii) a 5-HT2A receptor antagonist;

for use in the treatment and/or prevention of psychiatric and/or neurological disorders."

From **claim 9** "The combination product according to anyone of claims 2-8 for use in the treatment and/or prevention of a disorder selected from the group consisting of acquired brain injury, ataxia, **brain tumor**, dementia, dystonia, epilepsy, functional and dissociative neurological symptoms, meningitis, motor neuron disease, **multiple sclerosis**, muscular dystrophy, myalgic encephalomyelitis, Parkinson's disease, progressive supranuclear palsy, Huntington's disease, Alzheimer's disease, fronto-temporal dementia, vascular dementia, cognitive decline associated with aging, spina bifida, hydrocephalus, spinal injury, stroke, Tourette syndrome, transverse myelitis, panic disorder, agoraphobia, social

	anxiety disorder, phobias, post-traumatic stress disorder, obsessive compulsive disorder, **generalized anxiety disorder**, **bipolar disorder**, **depression**, anorexia nervosa, binge eating disorder, bulimia nervosa, **psychosis**, schizophrenia, **substance addiction** and personality disorders."
43. The method of claim 41, wherein the substance is chosen from the group consisting of cocaine, cannabis, alcohol, muscle relaxants, antihistamines, antidepressants, cardiovascular medications, antihypertensive medications, analgesics, anticonvulsants, anti-Parkinson medications, chemotherapy agents, corticosteroids, and psychedelics.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 2** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy; wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); **and** **(ii) a 5-HT2A receptor antagonist**;

	for use in the treatment and/or prevention of psychiatric and/or neurological disorders." From **claim 9** "The combination product according to anyone of claims 2-8 for use in the treatment and/or prevention of a disorder selected from the group consisting of acquired brain injury, ataxia, **brain tumor**, dementia, dystonia, epilepsy, functional and dissociative neurological symptoms, meningitis, motor neuron disease, **multiple sclerosis**, muscular dystrophy, myalgic encephalomyelitis, Parkinson's disease, progressive supranuclear palsy, Huntington's disease, Alzheimer's disease, fronto-temporal dementia, vascular dementia, cognitive decline associated with aging, spina bifida, hydrocephalus, spinal injury, stroke, Tourette syndrome, transverse myelitis, panic disorder, agoraphobia, social anxiety disorder, phobias, post-traumatic stress disorder, obsessive compulsive disorder, **generalized anxiety disorder**, **bipolar disorder**, depression, anorexia nervosa, binge eating disorder, bulimia nervosa, **psychosis**, schizophrenia, **substance addiction** and personality disorders." 2. VALERIANI (2015) "Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms" Human Psychopharmacology: Clinical and Experimental. 30:249-254. From **page 250** "In most cases, users reported here to **ingest olanzapine at relatively small dosages, usually ranging from 5 to 10 mg** once a day for just a few days **as a "terminator"/"modulator" of unwanted NPS psychedelic effects**." From **page 251** "Most online reports about olanzapine were here related to its use as a short-term, self-prescribed treatment for the psychedelic crises/"bad trips." Symptoms of psychedelic crises usually last a few hours, depending on the drug taken and dose ingested (Mangot, 2013). Indeed, SC's effects may last 1–4 h (Hoyte et al., 2012); tryptamines' effects 2–6 h (Hallock et al., 2013); lysergic acid diethylamide [LSD] 6–14 h (Krebs and Johansen, 2013); and mescaline 8–16 h (Trachsel, 2012)." From **page 251** "There are already published data showing the effectiveness of olanzapine and, in general, of second-generation antipsychotics (SGA), as first-line treatments in psychotic disorders induced by drugs such as cannabis (Bersani et al., 2002a, 2002b; Sevy et al., 2011) and cocaine (Testa et al., 2013). Compared with

first-generation antipsychotics (FGA), SGA may present with some advantages while treating drug-induced psychosis, including the following: (i) SGA induce fewer/no extrapyramidal symptoms (Ohno et al., 2013); (ii) SGA quickly dissociate from D2 receptors, unlike FGA/haloperidol, and hence may seem to be less associated with dysphoria and interference with drug reward anticipation/craving (Juckel et al., 2006); (iii) SGA seem more effective in the treatment of negative symptoms (Buchanan et al., 2005), alter positively mood (McIntyre et al., 2004), and have a positive impact on cognition (Bersani et al., 2011); and (iv) **SGA act as antagonists of 5HT2A receptor, which is the main target of most hallucinogenic drugs** (Potvin et al., 2003). From this point of view, **both clozapine and olanzapine may present with a distinct advantage in reducing drug-induced psychotic symptoms** (Murthy and Chand, 2012).

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 12** "Visualizations began at around 10:30 with crawling carpeting and changes in color hues. I felt as if my head was being detached from the rest of my body. Looking outside I noticed the color of the tree outside our home was leaning closer and closer to the window."

From **paragraph 12** "By around 10:45 - 11:00, the peak is in full swing and I am melting into the floor, **getting very intense, hard to see, my visual field is sideways and standing up straight becomes hard**. Wow, this is really good acid. **Maybe too good, I thought, this is only the beginning, time to cut this short**."

From **paragraph 13** "At 11:30 (or thereabouts) I consumed approx. 66mg of the Quetiapine."

From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit **cutting the LSD short**) from the psychedelic

	aspect of my trip using the Seroquel, **I would recommend it to anyone, at least to have as part of a psychedelic crisis kit.**" 7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psychedelicpassage.com/psychedelic-dosage-guide-how-much-of-each-substance-to-take/ "Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 – 150 µg (micrograms) per individual, 200+ µg in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 µg per tab**." 4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109 From **paragraph 5** "**Quetiapine has antagonist actions at 5-HT2A receptors**, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
44. The method of claim 41, wherein the duration shortening agent is administered 1 minute to 24 hours after administering the psychedelic drug.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 2** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:



wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;

wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;

wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and

wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;

wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); **and**

(ii) a 5-HT2A receptor antagonist;

for use in the treatment and/or prevention of psychiatric and/or neurological disorders."

From **claim 9** "The combination product according to anyone of claims 2-8 for use in the treatment and/or prevention of a disorder selected from the group consisting of acquired brain injury, ataxia, brain tumor, dementia, dystonia, epilepsy, functional and dissociative neurological symptoms, meningitis, motor neuron disease, multiple sclerosis, muscular dystrophy, myalgic encephalomyelitis, Parkinson's disease, progressive supranuclear palsy, Huntington's disease, Alzheimer's disease, fronto-temporal dementia, vascular dementia, cognitive decline associated with aging, spina bifida, hydrocephalus, spinal injury, stroke, Tourette syndrome, transverse myelitis, panic disorder, agoraphobia, social

	anxiety disorder, phobias, post-traumatic stress disorder, obsessive compulsive disorder, generalized anxiety disorder, bipolar disorder, depression, anorexia nervosa, binge eating disorder, bulimia nervosa, **psychosis**, schizophrenia, substance addiction and personality disorders." From **page 32** "In a preferred embodiment, a compound described by formula (I) may be administered to an individual who is already being administered a 5-HT2A receptor antagonist and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders. Conversely, in an alternative embodiment, **a 5-HT2A receptor antagonist may be administered to an individual who is already being administered a compound described by formula (I)** and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders." 2. VALERIANI (2015) "Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms" Human Psychopharmacology: Clinical and Experimental. 30:249-254. From **page 250** "In most cases, users reported here to **ingest olanzapine at relatively small dosages, usually ranging from 5 to 10 mg** once a day for just a few days **as a "terminator"/"modulator" of unwanted NPS psychedelic effects**." From **page 251** "Most online reports about olanzapine were here related to its use as a short-term, self-prescribed treatment for the psychedelic crises/"bad trips." Symptoms of psychedelic crises usually last a few hours, depending on the drug taken and dose ingested (Mangot, 2013). Indeed, SC's effects may last 1–4 h (Hoyte et al., 2012); tryptamines' effects 2–6 h (Hallock et al., 2013); lysergic acid diethylamide [LSD] 6–14 h (Krebs and Johansen, 2013); and mescaline 8–16 h (Trachsel, 2012)." From **page 251** "There are already published data showing the effectiveness of olanzapine and, in general, of second-generation antipsychotics (SGA), as first-line treatments in psychotic disorders induced by drugs such as cannabis (Bersani et al., 2002a, 2002b; Sevy et al., 2011) and cocaine (Testa et al., 2013). Compared with first-generation antipsychotics (FGA), SGA may present with some

advantages while treating drug-induced psychosis, including the following: (i) SGA induce fewer/no extrapyramidal symptoms (Ohno et al., 2013); (ii) SGA quickly dissociate from D2 receptors, unlike FGA/haloperidol, and hence may seem to be less associated with dysphoria and interference with drug reward anticipation/craving (Juckel et al., 2006); (iii) SGA seem more effective in the treatment of negative symptoms (Buchanan et al., 2005), alter positively mood (McIntyre et al., 2004), and have a positive impact on cognition (Bersani et al., 2011); and (iv) **SGA act as antagonists of 5HT2A receptor, which is the main target of most hallucinogenic drugs** (Potvin et al., 2003). From this point of view, **both clozapine and olanzapine may present with a distinct advantage in reducing drug-induced psychotic symptoms** (Murthy and Chand, 2012)."

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit."

7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psychedelicpassage.com/psychedelic-dosage-guide-how-much-of-each-substance-to-take/

"Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 – 150 µg (micrograms) per individual, 200+ µg in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 µg per tab**."

	4. GUZMAN (2016) “Mechanism of Action of Quetiapine” URL: https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109 From **paragraph 5** “**Quetiapine has antagonist actions at 5-HT2A receptors**, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3].”
45. The method of claim 41, wherein the psychedelic drug is a 5HT2A agonist chosen from the group consisting of LSD, psilocybin, psilocin, mescaline, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), dimethyltryptamine (DMT), 2,5-dimethoxy-4-iodoamphetamine (DOI), 2,5-dimethoxy-4-bromoamphetamie (DOB), salts thereof, tartrates thereof, solvates thereof, isomers thereof, deuterated forms thereof, analogs thereof, and homologues thereof.	1. Int’l Pat. Doc. No. WO/2019/081764 “COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS” (Published 02 May 2019) From **claim 2** “A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy; wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); **and**

(ii) a 5-HT2A receptor antagonist;

for use in the treatment and/or prevention of psychiatric and/or neurological disorders."

From **claim 3** "The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula (I)** is selected from the group consisting of **N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N-diethyltryptamine, N,N-dipropyltryptamine and N,N-diisopropyltryptamine.**"

From **claim 4** "The **combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is** selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, **Pimavanserin**, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK-215083, Cyamemazine, Mesulergine, BF-1 , LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150."

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit."

	7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psychedelicpassage.com/psychedelic-dosage-guide-how-much-of-each-substance-to-take/ "Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 – 150 µg (micrograms) per individual, 200+ µg in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 µg per tab**." 4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109 From **paragraph 5** "**Quetiapine has antagonist actions at 5-HT2A receptors**, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
46. The method of claim 41, wherein the psychedelic drug is administered in an amount that provides an effect for at least 2 hours.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 2** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;

	wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy; wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); **and** **(ii) a 5-HT2A receptor antagonist**; for use in the treatment and/or prevention of psychiatric and/or neurological disorders." From **claim 3** "The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula (I)** is selected from the group consisting of **N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N-diethyltryptamine, N,N-dipropyltryptamine and N,N-diisopropyltryptamine.**" From **claim 4** "The **combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is** selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, **Pimavanserin**, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK-215083, Cyamemazine, Mesulergine, BF-1 , LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150." From **claim 9** "The combination product according to anyone of claims 2-8 for use in the treatment and/or prevention of a disorder selected from the group consisting of acquired brain injury, ataxia, brain tumor, dementia, dystonia, epilepsy, functional and dissociative neurological symptoms, meningitis, motor neuron disease, multiple sclerosis, muscular dystrophy, myalgic encephalomyelitis, Parkinson's disease, progressive supranuclear palsy, Huntington's disease, Alzheimer's disease, fronto-temporal

	dementia, vascular dementia, cognitive decline associated with aging, spina bifida, hydrocephalus, spinal injury, stroke, Tourette syndrome, transverse myelitis, panic disorder, agoraphobia, social anxiety disorder, phobias, post-traumatic stress disorder, obsessive compulsive disorder, generalized anxiety disorder, bipolar disorder, depression, anorexia nervosa, binge eating disorder, bulimia nervosa, **psychosis**, schizophrenia, substance addiction and personality disorders." From **page 29** "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise **0.5 -1000 mg of a compound described by formula (I)** and/or 0.5 - 1000 mg of a 5-HT2A receptor antagonist." 3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844  From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit." 7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psychedelicpassage.com/psychedelic-dosage-guide-how-much-of-each-substance-to-take/ "Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 – 150 µg (micrograms) per individual, 200+ µg in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 µg per tab**."

	4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109 From **paragraph 5** "**Quetiapine has antagonist actions at 5-HT2A receptors**, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
47. The method of claim 45, wherein the psychedelic drug is administered in an amount chosen from the group consisting of 0.01-1 mg LSD, 10-50 mg psilocybin, 100-800 mg mescaline, 20-100 mg DMT, 0.1-5 mg DOI, and 0.1-5 mg DOB.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 2** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy; wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); **and**

	(ii) a 5-HT2A receptor antagonist; for use in the treatment and/or prevention of psychiatric and/or neurological disorders." From **claim 3** "The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula (I)** is selected from the group consisting of **N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N-diethyltryptamine, N,N-dipropyltryptamine and N,N-diisopropyltryptamine.**" From **claim 4** "The **combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is** selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, **Pimavanserin**, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK-215083, Cyamemazine, Mesulergine, BF-1 , LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150." From **claim 9** "The combination product according to anyone of claims 2-8 for use in the treatment and/or prevention of a disorder selected from the group consisting of acquired brain injury, ataxia, brain tumor, dementia, dystonia, epilepsy, functional and dissociative neurological symptoms, meningitis, motor neuron disease, multiple sclerosis, muscular dystrophy, myalgic encephalomyelitis, Parkinson's disease, progressive supranuclear palsy, Huntington's disease, Alzheimer's disease, fronto-temporal dementia, vascular dementia, cognitive decline associated with aging, spina bifida, hydrocephalus, spinal injury, stroke, Tourette syndrome, transverse myelitis, panic disorder, agoraphobia, social anxiety disorder, phobias, post-traumatic stress disorder, obsessive compulsive disorder, generalized anxiety disorder, bipolar disorder, depression, anorexia nervosa, binge eating disorder, bulimia nervosa, **psychosis**, schizophrenia, substance addiction and personality disorders." From **page 29** "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise **0.5 -1000 mg of**

	a compound described by formula (I) and/or 0.5 - 1000 mg of a 5-HT2A receptor antagonist." 3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844  From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit." 7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psychedelicpassage.com/psychedelic-dosage-guide-how-much-of-each-substance-to-take/ "Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 – 150 µg (micrograms) per individual, 200+ µg in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 µg per tab**." 4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109 From **paragraph 5** "**Quetiapine has antagonist actions at 5-HT2A receptors**, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."

48. The method of claim 41, wherein the duration shortening agent is a 5HT2A receptor antagonist.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 2** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:  wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy; wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); **and** **(ii) a 5-HT2A receptor antagonist**; for use in the treatment and/or prevention of psychiatric and/or neurological disorders." From **claim 3** "The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula (I)** is selected from the group consisting of **N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N-**

	diethyltryptamine, N,N-dipropyltryptamine and N,N-diisopropyltryptamine." From **claim 4** "The **combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is** selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, **Pimavanserin**, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK-215083, Cyamemazine, Mesulergine, BF-1 , LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150." From **claim 9** "The combination product according to anyone of claims 2-8 for use in the treatment and/or prevention of a disorder selected from the group consisting of acquired brain injury, ataxia, brain tumor, dementia, dystonia, epilepsy, functional and dissociative neurological symptoms, meningitis, motor neuron disease, multiple sclerosis, muscular dystrophy, myalgic encephalomyelitis, Parkinson's disease, progressive supranuclear palsy, Huntington's disease, Alzheimer's disease, fronto-temporal dementia, vascular dementia, cognitive decline associated with aging, spina bifida, hydrocephalus, spinal injury, stroke, Tourette syndrome, transverse myelitis, panic disorder, agoraphobia, social anxiety disorder, phobias, post-traumatic stress disorder, obsessive compulsive disorder, generalized anxiety disorder, bipolar disorder, depression, anorexia nervosa, binge eating disorder, bulimia nervosa, **psychosis**, schizophrenia, substance addiction and personality disorders." From **page 29** "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise **0.5 -1000 mg of a compound described by formula (I)** and/or 0.5 - 1000 mg of a 5-HT2A receptor antagonist." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**"

	3. PHARMBOY (2013) “Cheating Hofmann - LSD, Quetiapine & Alcohol” Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844  From **paragraph 25** “Considering how easy and smooth it felt coming down (albeit **cutting the LSD short**) **from the psychedelic aspect of my trip using the Seroquel**, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit.” 7. LEVICH (2020) “Psychedelic Dosage Guide: How Much of Each Substance to Take” Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psychedelicpassage.com/psychedelic-dosage-guide-how-much-of-each-substance-to-take/ “Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 – 150 µg (micrograms) per individual, 200+ µg in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 µg per tab**.” 4. GUZMAN (2016) “Mechanism of Action of Quetiapine” URL: https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109 From **paragraph 5** “**Quetiapine has antagonist actions at 5-HT2A receptors**, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3].”
49. The method of claim 48, wherein the duration shortening agent is chosen from the group consisting of pimavanserin, salts	1. Int’l Pat. Doc. No. WO/2019/081764 “COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS” (Published 02 May 2019) From **claim 2** “A **pharmaceutical combination product comprising: compound described by the following formula (I)**:

thereof, analogs thereof, and homologs thereof.	 wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy; wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); **and** **(ii) a 5-HT2A receptor antagonist**; for use in the treatment and/or prevention of psychiatric and/or neurological disorders." From **claim 3** "The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula (I)** is selected from the group consisting of **N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N-diethyltryptamine, N,N-dipropyltryptamine and N,N-diisopropyltryptamine.**" From **claim 4** "The **combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is** selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone,

	Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, **Pimavanserin**, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK-215083, Cyamemazine, Mesulergine, BF-1 , LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150." From **claim 9** "The combination product according to anyone of claims 2-8 for use in the treatment and/or prevention of a disorder selected from the group consisting of acquired brain injury, ataxia, brain tumor, dementia, dystonia, epilepsy, functional and dissociative neurological symptoms, meningitis, motor neuron disease, multiple sclerosis, muscular dystrophy, myalgic encephalomyelitis, Parkinson's disease, progressive supranuclear palsy, Huntington's disease, Alzheimer's disease, fronto-temporal dementia, vascular dementia, cognitive decline associated with aging, spina bifida, hydrocephalus, spinal injury, stroke, Tourette syndrome, transverse myelitis, panic disorder, agoraphobia, social anxiety disorder, phobias, post-traumatic stress disorder, obsessive compulsive disorder, generalized anxiety disorder, bipolar disorder, depression, anorexia nervosa, binge eating disorder, bulimia nervosa, **psychosis**, schizophrenia, substance addiction and personality disorders." From **page 29** "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise **0.5 -1000 mg of a compound described by formula (I)** and/or 0.5 - 1000 mg of a 5-HT2A receptor antagonist." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**"
50. The method of claim 49, wherein the pimavanserin is administered in an amount of 1-100 mg.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From **claim 2** "A **pharmaceutical combination product comprising: compound described by the following formula (I)**:



wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;

wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;

wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and

wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;

wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); **and**

(ii) a 5-HT2A receptor antagonist;

for use in the treatment and/or prevention of psychiatric and/or neurological disorders."

From **claim 3** "The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula (I)** is selected from the group consisting of **N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N-diethyltryptamine, N,N-dipropyltryptamine and N,N-diisopropyltryptamine.**"

From **claim 4** "The **combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is** selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone,

	Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, **Pimavanserin**, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK-215083, Cyamemazine, Mesulergine, BF-1 , LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150." From **claim 9** "The combination product according to anyone of claims 2-8 for use in the treatment and/or prevention of a disorder selected from the group consisting of acquired brain injury, ataxia, brain tumor, dementia, dystonia, epilepsy, functional and dissociative neurological symptoms, meningitis, motor neuron disease, multiple sclerosis, muscular dystrophy, myalgic encephalomyelitis, Parkinson's disease, progressive supranuclear palsy, Huntington's disease, Alzheimer's disease, fronto-temporal dementia, vascular dementia, cognitive decline associated with aging, spina bifida, hydrocephalus, spinal injury, stroke, Tourette syndrome, transverse myelitis, panic disorder, agoraphobia, social anxiety disorder, phobias, post-traumatic stress disorder, obsessive compulsive disorder, generalized anxiety disorder, bipolar disorder, depression, anorexia nervosa, binge eating disorder, bulimia nervosa, **psychosis**, schizophrenia, substance addiction and personality disorders." From **page 29** "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise **0**.5 -1000 mg of a compound described by formula (I) and/or **0.5 - 1000 mg of a 5-HT2A receptor antagonist**." From **page 32** "In a preferred embodiment, the **5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I).**" 8. FDA (2016) "NUPLAZID (PIMAVANSERIN): HIGHLIGHTS OF PRESCRIBING INFORMATION" URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf From **page 1** "DOSAGE AND ADMINISTRATION: **Recommended dose is 34 mg**, taken orally as two 17 mg tablets once daily, without titration.

Electronic Acknowledgement Receipt

EFS ID:	47816445
Application Number:	17833829
International Application Number:	
Confirmation Number:	4702
Title of Invention:	CONTROLLING EFFECTS AFTER 5HT2A AGONISTS ADMINISTRATION
First Named Inventor/Applicant Name:	Daniel R. KARLIN
Customer Number:	48924
Filer:	Shahin Shams
Filer Authorized By:	
Attorney Docket Number:	0614.00142
Receipt Date:	10-APR-2023
Filing Date:	06-JUN-2022
Time Stamp:	15:02:50
Application Type:	

Payment information:

Submitted with Payment	yes
Payment Type	CARD
Payment was successfully received in RAM	$72
RAM confirmation Number	E202340F02448302
Deposit Account	
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Concise Description of Relevance	Concise-description-generated.pdf	48337 a11054f8b61af065fd19149cb5822652b4d046ea	no	9
Warnings:					
Information:					
2	Third-Party Submission Under 37 CFR 1.290	Third-party-preissuance-submission.pdf	71269 8b4afbfcf1a587e41f0ffb54278721c4eb21b6c2	no	5
Warnings:					
Information:					
3	Request for Notification of Non-compliant Third-Party Submission	Third-party-notification-request.pdf	23721 2aa887b2b082cb0560bb7c9cd3218e074777990b	no	1
Warnings:					
Information:					
4	Concise Description of Relevance	US20220395499ClaimsChartComp.pdf	566867 30ce2233a1454e4957822ad164c722199081af2a	no	116
Warnings:					
Information:					
5	Evidence of Publication	1-WO2019081764AsFiledComp.pdf	701437 48868c73c78727322f643830337480839fa1de01	no	64
Warnings:					
Information:					
6	Evidence of Publication	2-Valeriani2015.pdf	160452 685f6afcdc5f2ecfa41e2009ff53d2f7c0653b6e	no	6
Warnings:					
Information:					

7	Evidence of Publication	3-PHARMBOYComp.pdf	500446 c6727faad88b8562cd75c746c56417f4d25b272b	no	3
Warnings:					
Information:					
8	Evidence of Publication	4-GUZMAN.pdf	639874 651c6f5c043f6329d3a7028526a321d1bb761977	no	4
Warnings:					
Information:					
9	Evidence of Publication	5-MAHATMAGANJA.pdf	184780 27dbd33e2aff81f890621be12fce8881c985b819	no	1
Warnings:					
Information:					
10	Evidence of Publication	6-BIGWOODComp5.pdf	863469 c36dc3497a1bce7e474ca23504fb5a6e64e290ab	no	5
Warnings:					
Information:					
11	Evidence of Publication	7-LEVICH.pdf	13674060 4753cbc77f3f241156d2f2bca2cb5f7fc070afa2	no	16
Warnings:					
Information:					
12	Evidence of Publication	8-NUPLAZIDComp.pdf	277818 bb9a382bcae36a65ef9942e78ddefc20e7aa5b2a	no	1
Warnings:					
Information:					
13	Evidence of Publication	9-NIMH.pdf	370938 503b3c5af78e792e0032f9f6a974ee90e7fc08fb	no	3
Warnings:					
Information:					

14	Fee Worksheet (SB06)	fee-info.pdf	37327 23d2ec2d48fc23703c6c88719fe1a0b6029fa763	no	2

Warnings:	
Information:	
Total Files Size (in bytes):	18120795

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.